Back to results
US 12,589,156 B2Granted
Benzimidazole and benzimidazolone based protac compounds for the targeted degradation of leucine rich repeat kinase 2 (LRRK2)
AssigneeArvinas Operations, Inc.
InventorsSteven M. Sparks, Michael Berlin
Life of this patent
Estimating the term…
Abstract
Provided herein are compounds (e.g., compounds of Formula (Ia)) that function to recruit LRRK2 protein or a mutated version thereof to an E3 ubiquitin ligase for targeted ubiquitination and subsequent proteasomal degradation.
Claims12
A compound, wherein the compound is:
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.